Pomalidomide-induced hypothyroidism

Pomalidomide-induced hypothyroidism

Hypothyroidism is a recognized side effect of thalidomide drugs. We herein report a case of 83-year-old Irish female with a diagnosis of multiple myeloma and a background history of type 2 diabetes mellitus and hypertension. Our patient received pomalidomide and multiple courses of chemotherapy and...

Full description

Bibliographic Details
Main Authors:	Sulaiman Haji Ali, K Aljenaee, W A Wan Mahmood, M Hatunic
Format:	Article
Language:	English
Published:	Bioscientifica 2017-12-01
Series:	Endocrinology, Diabetes & Metabolism Case Reports
Online Access:	https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-17-0110

Similar Items

Pomalidomide induced lupus type hypersensitivity reaction
by: Chinmay Jani, et al.
Published: (2021-03-01)

Severe primary hypothyroidism in an apparently asymptomatic 19-year-old woman: a case report
by: Rania Dannan, et al.
Published: (2021-03-01)

Pomalidomide Reduces Ischemic Brain Injury in Rodents
by: Yan-Rou Tsai, et al.
Published: (2019-04-01)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
by: Gowin KL, et al.
Published: (2015-04-01)

Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
by: Rios-Tamayo R, et al.
Published: (2017-08-01)

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
by: Mary H. Young, et al.
Published: (2021-08-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Distribution of pomalidomide into semen of healthy male subjects after multiple doses
by: Li Y, et al.
Published: (2018-05-01)

Development and Validation of Pomalidomide Determination in Human Plasma by HPLC-MS/MS Method
by: T. N. Komarov, et al.
Published: (2020-11-01)

Comparison of the modulation of FGFR signalling by thalidomide and its analogs lenalidomide and pomalidomide
by: Lakshmikirupa Sundaresan, et al.
Published: (2017-10-01)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
by: Terpos E, et al.
Published: (2013-05-01)

Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer
by: Robert Knight, et al.
Published: (2011-09-01)

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
by: Hao-Wei Wang, et al.
Published: (2021-02-01)

Inhibition of Airway Contraction and Inflammation by Pomalidomide in a Male Wistar Rat Model of Ovalbumin-induced Asthma
by: Majid Ghaderi, et al.
Published: (2019-04-01)

The Role of Pomalidomide-Based Epigenetic Effect on DNMT Genes Expression in Myeloma Cell Line
by: Ali Dehghani Fard, et al.
Published: (2018-06-01)

Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma
by: AV Petrov, et al.
Published: (2017-07-01)

Inclusion complexation of the anticancer drug pomalidomide with cyclodextrins: fast dissolution and improved solubility
by: Zoltán-István Szabó, et al.
Published: (2021-07-01)

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
by: Manh-Cuong Vo, et al.
Published: (2018-08-01)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
by: Paul G. Richardson, et al.
Published: (2021-03-01)

Pomalidomide Attenuates Inflammation, Oxidative Stress Responses and Apoptosis in Ischemic Brain Injury
by: Yan-Rou Tsai, et al.
Published: (2019)

The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
by: IG Rekhtina, et al.
Published: (2018-10-01)

Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells
by: David A. Davis, et al.
Published: (2019-02-01)

35 Therapy with the immunomodulatory agent pomalidomide does not lead to changes in HIV-1 viral populations in vivo
by: S.A. Watters, et al.
Published: (2016-07-01)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
by: Anderson, L.D., Jr, et al.
Published: (2022)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
by: Brian J North, et al.
Published: (2017-01-01)

Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
by: Prabha Shrestha, et al.
Published: (2021-01-01)

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
by: Li Y, et al.
Published: (2017-11-01)

Amiodarone-Induced Hypothyroidism
by: Svetlana A. Chepurnenko, et al.
Published: (2019-12-01)

Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
by: Marina Silvia Parisi, et al.
Published: (2019-10-01)

Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease
by: Maria Antonietta Casu, et al.
Published: (2020-02-01)

Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.
by: Zhimin Li, et al.
Published: (2013-01-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)

Pulmonary consequences of hypothyroidism
by: Mahmood Dhahir Al-Mendalawi
Published: (2018-01-01)

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study
by: Evangelos Terpos, et al.
Published: (2021-04-01)

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS
by: M.E.Z. Capra, et al.
Published: (2020-11-01)

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma
by: Teresa Paíno, et al.
Published: (2020-09-01)

Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
by: Jason Fangusaro, et al.
Published: (2021-06-01)